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Antihistaminic activityAbstract In the present study a series of 1-substituted-4-(3-chlorophenyl)-[1,2,4] triazolo [4,3-a]
quinazolin-5(4H)-ones were synthesized and screened for their H1-antihistaminic activity. The syn-
thesized compounds were characterized by IR, 1H-NMR, mass spectral data and purity of the com-
pounds was determined by elemental analysis. Antihistaminic activity of the title compounds was
evaluated by histamine induced bronchoconstriction method in guinea pigs. Among the series, 4-
(3-chlorophenyl)-1-methyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (S5) was the most potent with
the percentage protection of 69.65% and its potency is comparable to the reference drug chlorphe-
niramine maleate (70.09% protection). Interestingly the sedative property of compound S5 was
found to be negligible (5.36%) when compared to chlorpheniramine maleate (34.92%).
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The ﬁrst generation anti-histamines like pheniramine and
diphenhydramine are associated with sedation and anticholin-
ergic properties as the major side effects; this has led to the
development of second generation H1-antagonists such as ter-fenadine, cetirizine and astemizole (Simons and Simons, 1994).
A common feature of ﬁrst generation compounds includes two
aryl or heteroaryl rings linked to an aliphatic tertiary amine via
the side chain (Ellis et al., 1985), the second-generation com-
pounds (terfenadine and cetirizine) also contain many of the
structural features of the ﬁrst generation compounds. The real
breakthrough of non-sedative antihistamines came in the early
eighties of the twentieth century when the discovery of modern
antihistamines, was found to exhibit potent antihistaminic
activity without sleep-inducing effects (Carr and Meyer,
1982). Condensed heterocycles containing a new generation
of H1-antihistamines (e.g. loratadine, azelastine and ﬂazelas-
tine) that do not possess the above mentioned pharmacophore
for H1-antihistamines gave way for the discovery of many
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1985; Chairungsrilerd et al., 1996). Quinazolinones are associ-
ated with a wide range of biological and pharmacological
activities such as analgesic (Mallareddy and Sattur, 1984),
anti-inﬂammatory (Mallareddy et al., 1987), antifungal (Ku-
mar et al., 1997; Bartroli et al., 1998), antiviral (Mukherji
et al., 1980) and antihistaminic activities (Raghuramrao
et al., 1986; Devsingh et al., 2001; Raju et al., 1999). In this
continuation we demonstrated that the quinazolinone deriva-
tives are potent antihistamines with least sedation (Alagarsamy
et al., 2002; Alagarsamy, 2004). The present work is an exten-
sion of our ongoing efforts towards the development and iden-
tiﬁcation of new quinazolinone derived antihistaminics; thus
we aimed to synthesize a series of 1-substituted-4-(3-chloro-
phenyl)-[1,2,4] triazolo [4,3-a]quinazolin-5(4H)-ones (Scheme.
1). The synthesized compounds were tested for their in vivo
H1-antihistaminic activity on conscious guinea pigs. As seda-
tion is one of the major side effects associated with antihista-
mines, the test compounds were also evaluated for their
sedative potentials, by measuring the reduction in locomotor
activity using actophotometer.
2. Materials and methods
2.1. General
Melting points (mp) were taken in open capillaries on a
Thomas Hoover melting point apparatus (Thomas Hoover,
Philadelphia, USA) and are uncorrected. The IR spectra were
recorded in ﬁlm or in potassium bromide disks on a Perkin-
Elmer 398 spectrometer (Bio Engineering, Wald, Switzerland).N
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Scheme 1 Synthesis of 1-substituted-4-(3-chlorophenyl)-
[1,2,4]triazolo [4,3-a]quinazolin-5(4H)-ones.The 1H spectra were recorded on a DPX-500 MHz Bruker FT-
NMR spectrometer (Paciﬁc Northwest, Richland, Washing-
ton, USA). The chemical shifts were reported as parts per mil-
lion (dppm) tetramethylsilane (TMS) as an internal standard.
Mass spectra were obtained on a JEOL-SX-102 instrument
(Masspec, Tokyo, Japan) using fast atom bombardment
(FAB positive). Elemental analysis was performed on a Per-
kin-Elmer 2400 CHN analyzer and values were within the
acceptable limits of the calculated values (±0.4%). The pro-
gress of the reaction was monitored on readymade silica gel
plates (Merck Whitehouse Station, NJ, USA) using chloro-
form/methanol (9:1) as a solvent system. Iodine was used as
a developing agent. All chemicals and reagents used in the syn-
thesis were obtained from Aldrich (Sigma–Aldrich, Spruce St.,
St. Louis, MO 63103), Lancaster (Alfa Aesar, Johnson Mat-
they Company, Ward Hill, MA 01835, USA) or Spectrochem
Pvt. Ltd. (Mumbai, India) and were used without further
puriﬁcation.
2.2. Chemistry
2.2.1. Synthesis of 3-(3-chlorophenyl)-2-thioxo-quinazolin-
4(3H)-one (S1)
A solution of the 3-chloro aniline (0.02 mol) in dimethyl sulf-
oxide (10 mL) was stirred vigorously. To this carbon disulﬁde
(1.6 mL) and aqueous sodium hydroxide (1.2 mL, 20 M) were
added dropwise during 30 min with stirring. Dimethyl sulfate
(2.5 g, 0.02 mol) was added gradually with stirring by keeping
the reaction mixture in a freezing mixture for 2 h. The reaction
mixture was then poured into ice water. The solid obtained
was ﬁltered, washed with water, dried and recrystallized from
ethanol.
Methyl anthranilate (1.5 g, 0.01 mol) and the above pre-
pared N-(3-chlorophenyl)-methyl dithiocarbamic acid
(0.01 mol), were dissolved in ethanol (20 mL). To this anhy-
drous potassium carbonate (100 mg) was added and reﬂuxed
for 19 h. The reaction mixture was cooled in ice and the solid
separated was ﬁltered and puriﬁed by dissolving in 10% alco-
holic sodium hydroxide solution and re-precipitated by treat-
ing with dilute hydrocholoric acid. The solid obtained was
ﬁltered, washed with water, dried and recrystallized from
ethanol.
2.2.1.1. 3-(3-chlorophenyl)-2-thioxo-quinazolin-4(3H)-one
(S1). Yield = 86%, mp 305–306 C, IR: (KBr, cm1) 3243
(NH), 1660 (C‚O), 1231 (C‚S). 1H NMR: (500 MHz,
CDCl3) dppm: 6.74 (s, 1H, Ar-H), 6.84 (s, 1H, Ar-H), 6.98
(s, 1H, Ar-H), 7.15 (s, 1H, Ar-H), 7.22–7.25 (m, 2H, Ar-H),
7.68–7.70 (m, 2H, Ar-H), 10.12 (br s, 1H, NH). ESI-MS:
MS: m/z 288 [M+], Anal. Cald. for C14H9ClN2OS: C, 58.23;
H, 3.14; N, 9.70. Found: C, 58.39; H, 3.12; N, 9.71.
2.2.2. Synthesis of 3-(3-chlorophenyl)-2-methylthio quinazolin-
4(3H)-one (S2)
3-(3-chlorophenyl)-2-thioxo-quinazolin-4(3H)-one (S1) (0.01
mol) was dissolved in 20 mL of 2% alcoholic sodium
hydroxide solution. To this dimethyl sulfate (1.26 g,
0.01 mol) was added dropwise with stirring and stirring was
continued for 1 h after completion of addition. The reaction
mixture was then poured into ice water. The solid obtained
was ﬁltered, washed with water, dried and recrystallized from
ethanol-chloroform (75:25) mixture.
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(S2). Yield: 89%, mp: 165–166 C, IR: (KBr, cm1) 1685
(C‚O), 1607 (C‚N). 1H NMR: (500 MHz, CDCl3) dppm:
2.49 (s, 3H, SCH3), 6.73 (s, 1H, Ar-H), 6.83 (s, 1H, Ar-H),
6.95 (s, 1H, Ar-H), 7.14 (s, 1H, Ar-H), 7.24–7.26 (m, 2H,
Ar-H), 7.70–7.72 (m, 2H, Ar-H). ESI-MS: MS: m/z 302
[M+]; Anal. Cald. for C15H11ClN2OS: C, 59.50; H, 3.66; N,
9.25. Found: C, 59.25; H, 3.69; N, 9.24.
2.2.3. Synthesis of 3-(3-chlorophenyl)-2-hydrazino quinazolin-
4(3H)-one (S3)
3-(3-chlorophenyl)-2-methylthio quinazolin-4(3H)-one (S2)
(0.01 mol) was dissolved in ethanol (25 mL). To this hydrazine
hydrate (5.0 g, 0.1 mol) and anhydrous potassium carbonate
(100 mg) were added and reﬂuxed for 24 h. The reaction mix-
ture was cooled and poured into ice-water. The solid obtained
was ﬁltered, washed with water, dried and recrystallized from
chloroform-benzene (50:50) mixture.
2.2.3.1. 3-(3-Chlorophenyl)-2-hydrazino quinazolin-4(3H)-one
(S3). Yield: 81%, mp 193–194 C, IR: (KBr, cm1) 3313, 3300
(NHNH2), 1673 (C‚O).
1H NMR: (500 MHz, CDCl3) dppm:
4.65 (br s, 2H, NH2), 6.98 (s, 1H, Ar-H), 7.19 (s, 1H, Ar-H),
7.38–7.40 (m, 2H, Ar-H), 7.48–7.51 (m, 2H, Ar-H), 7.67 (s,
1H, Ar-H), 7.85 (s, 1H, Ar-H), 8.52 (br s, 1H, NH). ESI-
MS: MS: m/z 286 [M+]; Anal. Cald. for C14H11ClN4O: C,
58.64; H, 3.86; N, 19.54. Found: C, 58.63; H, 3.88; N, 19.56.
2.2.4. Synthesis of 4-(3-chlorophenyl)-[1,2,4]triazolo[4,3-
a]quinazolin-5(4H)-one (S4)
3-(3-chlorophenyl)-2-hydrazino quinazolin-4(3H)-one (S3)
(0.01 mol) and formic acid (15 mL) were taken in a round bot-
tomed ﬂask and reﬂuxed for 29 h, cooled and poured into ice
water. The solid obtained was ﬁltered, washed with water,
dried and recrystallized from chloroform-ethanol (75:25)
mixture.
2.2.4.1. 4-(3-Chlorophenyl)-[1,2,4]triazolo[4,3-a]quinazolin-
5(4H)-one (S4). Yield: 80%, mp. 251–252 C, IR: (KBr, cm
1) 1670 (C‚O), 1607 (C‚N). 1H NMR: (500 MHz, CDCl3)
dppm: 6.95 (s, 1H, Ar-H), 7.16 (s, 1H, Ar-H), 7.35–7.38 (m,
2H, Ar-H), 7.50–7.53 (m, 2H, Ar-H), 7.71 (s, 1H, Ar-H),
7.88 (s, 1H, Ar-H), 9.41 (s, 1H, Ar-H). ESI-MS: MS: m/z
296 [M+]; Anal. Cald. for C15H9ClN4O: C, 60.72; H, 3.06;
N, 18.88. Found: C, 60.74; H, 3.05; N, 18.84.
2.2.5. Synthesis of 4-(3-chlorophenyl)-1-methyl-
[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (S5)
3-(3-chlorophenyl)-2-hydrazino quinazolin-4(3H)-one (S3)
(0.01 mol) and acetic acid (15 mL) were taken in a round bot-
tomed ﬂask and reﬂuxed for 31 h, cooled and poured into ice
water. The solid obtained was ﬁltered, washed with water,
dried and recrystallized from ethanol.
2.2.5.1. 4-(3-Chlorophenyl)-1-methyl-[1,2,4]triazolo[4,3-
a]quinazolin-5(4H)-one (S5). Yield. 85%, mp. 227–228 C,
IR: (KBr, cm1) 1688 (C‚O), 1604 (C‚N). 1H NMR:
(500 MHz, CDCl3) dppm: 2.49 (s, 3H, CH3), 6.97 (s, 1H,
Ar-H), 7.18 (s, 1H, Ar-H), 7.33–7.35 (m, 2H, Ar-H), 7.48–
7.51 (m, 2H, Ar-H), 7.70 (s, 1H, Ar-H), 7.90 (s, 1H, Ar-H).
13C NMR: (125 MHz, CDCl3) dppm: 9.47, 117.87, 121.78,123.64, 126.49, 127.67, 129.44, 129.75, 131.73, 131.87, 133.27,
134.81, 136.81, 148.95, 149.74, 158.98. ESI-MS: MS: m/z 310
[M+], Anal. Cald. for C16H11ClN4O: C, 61.84; H, 3.57; N,
18.03. Found: C, 61.89; H, 3.59; N, 18.06.
2.2.6. Synthesis of 4-(3-chlorophenyl)-1-ethyl-
[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (S6)
3-(3-chlorophenyl)-2-hydrazino quinazolin-4(3H)-one (S3)
(0.01 mol) and propionic acid (15 mL) were taken in a round
bottomed ﬂask and reﬂuxed for 26 h, cooled and poured into
ice water. The solid obtained was ﬁltered, washed with water,
dried and recrystallized from ethanol.
2.2.6.1. 4-(3-Chlorophenyl)-1-ethyl-[1,2,4]triazolo[4,3-a]qui-
nazolin-5(4H)-one (S6). Yield. 80%, mp. 247–249 C, IR:
(KBr, cm1) 1678 (C‚O), 1611 (C‚N). 1H NMR:
(500 MHz, CDCl3) dppm: 1.33–1.36 (t, 3H, CH3), 2.72–2.77
(q, 2H, CH2), 6.99 (s, 1H, Ar-H), 7.20 (s, 1H, Ar-H), 7.39–
7.41 (m, 2H, Ar-H), 7.51–753 (m, 2H, Ar-H), 7.69 (s, 1H,
Ar-H), 7.87 (s, 1H, Ar-H). ESI-MS: MS: m/z 324 [M+], Anal.
Cald. for C17H13ClN4O: C, 62.87; H, 4.03; N, 17.25. Found: C,
62.88; H, 4.06; N, 17.24.
2.2.7. Synthesis of 4-(3-chlorophenyl)-1-propyl-
[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (S7)
3-(3-chlorophenyl)-2-hydrazino quinazolin-4(3H)-one (S3)
(0.01 mol) and butyric acid (15 mL) were taken in a round bot-
tomed ﬂask and reﬂuxed for 24 h, cooled and poured into ice
water. The solid obtained was ﬁltered, washed with water,
dried and recrystallized from ethanol.
2.2.7.1. 4-(3-Chlorophenyl)-1-propyl-[1,2,4]triazolo[4,3-a]qui-
nazolin-5(4H)-one (S7). Yield. 80%, mp. 273–274 C, IR:
(KBr, cm1) 1705 (C‚O), 1608 (C‚N). 1H NMR:
(500 MHz, CDCl3) dppm: 0.95–1.00 (t, 3H, CH3), 1.74–1.82
(m, 2H, CH2), 2.70–2.76 (t, 2H, CH2), 6.98 (s, 1H, Ar-H),
7.19 (s, 1H, Ar-H), 7.40–7.42 (m, 2H, Ar-H), 7.48–7.51 (m,
2H, Ar-H), 7.67 (s, 1H, Ar-H), 7.87 (s, 1H, Ar-H). ESI-MS:
MS: m/z 338 [M+], Anal. Cald. for C18H15ClN4O: C, 63.81;
H, 4.46; N, 16.64. Found: C, 63.84; H, 4.47; N, 16.63.
2.2.8. Synthesis of 1-(chloromethyl)-4-(3-chlorophenyl)-
[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (S8)
3-(3-chlorophenyl)-2-hydrazino quinazolin-4(3H)-one (S3)
(0.01 mol) and chloroacetyl chloride (0.01 mol) in glacial acetic
acid (15 mL) were taken in a round bottomed ﬂask and re-
ﬂuxed for 13 h, cooled and poured into ice water. The solid ob-
tained was ﬁltered, washed with water, dried and recrystallized
from chloroform-ethanol (75:25) mixture.
2.2.8.1. 1-(Chloromethyl)-4-(3-chlorophenyl)-[1,2,4]triazol-
o[4,3-a]quinazolin-5(4H)-one (S8). Yield: 81%, mp. 285–
286 C, IR: (KBr, cm1) 1687 (C‚O), 1608 (C‚N). 1H
NMR: (500 MHz, CDCl3) dppm: 2.49 (s, 2H, CH2Cl), 6.96
(s, 1H, Ar-H), 7.17 (s, 1H, Ar-H), 7.37–7.39 (m, 2H, Ar-H),
7.50–7.52 (m, 2H, Ar-H), 7.69 (s, 1H, Ar-H), 7.83 (s, 1H,
Ar-H). 13C NMR: (125 MHz, CDCl3) dppm: 116.98, 121.88,
123.74, 126.89, 128.47, 129.64, 129.89, 131.88, 132.98, 134.17,
134.65, 136.92, 148.95, 149.74, 158.87. ESI-MS: MS: m/z 345
[M+], Anal. Cald. for C16H10Cl2N4O: C, 55.67; H, 2.92; N,
16.23. Found: C, 55.65; H, 2.93; N, 16.26.
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The synthesized compounds were evaluated for antihistaminic
and sedative-hypnotic activities. The animals were maintained
in colony cages at 25 ± 2 C, relative humidity of 45–55%, un-
der a 12 h light and dark cycle; they were fed standard animal
feed. All the animals were acclimatized for a week before use.
The Institutional Animal Ethics committee approved the pro-
tocol adopted for the experimentation of animals.
3.1. Antihistaminic activity
A modiﬁcation of the technique of Van Arman was adopted to
determine the antihistaminic potential of the synthesized com-
pounds (Van Arman et al., 1961). Male Dunkin Hartley Gui-
nea pigs (250–300 g) were fasted for 12 h. Six animals were
taken in each group. The test compounds, were administered
orally at a dose of 10 mg/kg in 1% CMC and challenged with
histamine aerosol (0.2% aqueous solution of histamine acid
chloride 3 mL) in a vaponephrine pocket nebulizer sprayed
into a closed transparent cage. The respiratory status reﬂecting
the increasing degree of bronchoconstriction was recorded.
The time for onset of convulsions (preconvulsion) was re-
corded. Animals remaining stable for more than 6 min were
considered protected against histamine-induced broncho-
spasm. An intraperitoneal injection of chlorpheniramine male-
ate (Hoechst, Mumbai, India) at a dose of 25 mg/kg was given
for the recovery of the test animals. The mean preconvulsion
time of animals, treated with the test compounds was com-
pared to the control and is expressed in terms of percentage
protection (Table 1).
 Percent protection = [1  (T1/T2)] · 100
 T1 – preconvulsive time of control; T2 – preconvulsive time
of test compound.
 The activity of the test compounds was compared with the
standard antihistamine chlorpheniramine maleate.
3.2. Sedative-hypnotic activity
Sedative-hypnotic activity was determined by measuring the
reduction in locomotor activity using actophotometer (Dews,
1953; Kuhn and Van Maanen, 1961). Swiss albino mice were
chosen as test animals in a group of six. Basal activity score
was taken and then compounds S4–S8 and standard chlorphe-
niramine maleate were administered orally at the dose ofTable 1 Antihistaminic and sedative-hypnotic activity of compoun
Compound code Histamine-induced bronchospasm (s) Protect
S4 380.00 ± 4.56** 68.92 ±
S5 389.00 ± 2.92** 69.65 ±
S6 382.50 ± 4.56** 69.12 ±
S7 360.83 ± 4.02** 67.26 ±
S8 350.00 ± 4.74** 66.25 ±
Chlorpheniramine 394.10 ± 4.43** 70.09 ±
Each value represents the mean ± SEM (n= 6).
** Statistical signiﬁcance: p< 0.05.5 mg/kg in 1% CMC. Scores were recorded at 1, 2 and 3 h
after the drug administration. The percent reduction in loco-
motor activity was calculated by the following formula and
shown in Table 1.
ﬁ% Reduction in motor activity = [(A  B)/A] · 100
ﬁWhere A-basal score, B-score after drug treatment.
3.3. Statistical analysis
Statistical analysis of the biological activity of the test com-
pounds on various animals was performed by one way ANO-
VA followed by dunnett’s test (manually). In all cases
signiﬁcance level of the means of individual groups were per-
formed and compared with the control. A signiﬁcance level
of p< 0.5 denoted signiﬁcance in all cases.
4. Results and discussion
4.1. Chemistry
The key intermediate 3-(3-chlorophenyl)-2-thioxo-quinazolin-
4(3H)-one (S1), was prepared by reacting 3-chloro aniline with
carbon disulﬁde and sodium hydroxide in dimethyl sulphoxide
to give sodium dithiocarbamate, which was methylated with
dimethyl sulphate to afford the dithiocarbamic acid methyl es-
ter, which upon reﬂux with methyl anthranilate in ethanol
yielded the desired 3-(3-chlorophenyl)-2-thioxo-quinazolin-
4(3H)-one (S1) via the thiourea intermediate in good yield
(86%). The product obtained was cyclic and not an open chain
thiourea. 3-(3-chlorophenyl)-2-(methylthio) quinazolin-4(3H)-
one S2 was obtained by dissolving S1 in 2% alcoholic sodium
hydroxide solution and methylating with dimethyl sulfate with
stirring at room temperature. Nucleophilic displacement of
methylthio group of S2 with hydrazine hydrate was carried
out using ethanol as solvent to afford 3-(3-chlorophenyl) 2-
hydrazinyl-quinazolin-4(3H)-one S3. The long duration of
reaction (24 h) required might be due to the presence of bulky
aromatic ring at position 3, which might have reduced the
reactivity of the quinazoline ring system at the C-2 position.
The title compounds S4-S8 were obtained in fair to good yields
through the cyclization of S3 with a variety of one carbon do-
nors such as formic acid, acetic acid, propionic acid, butyric
acid and chloroacetyl chloride at reﬂux. The 1H NMR spec-ds (S4–S8).
ion (%) Percent CNS depression
1 h 2 h 3 h
0.38** 7.56 ± 0.06** 9.29 ± 0.06** 4.75 ± 0.23**
0.22** 9.13 ± 0.07** 10.16 ± 0.03** 5.36 ± 0.04**
0.36** 9.64 ± 0.09** 11.16 ± 0.08** 5.27 ± 0.06**
0.36** 10.52 ± 0.04** 10.86 ± 0.04** 5.43 ± 0.15**
0.46** 6.54 ± 0.04** 7.47 ± 0.18** 4.35 ± 0.02**
0.33** 38.80 ± 1.32** 34.80 ± 0.72** 29.58 ± 0.72**
286 M. Gobinath et al.trum of S4–S8 showed the absence of NH and NH2 signals.
All the synthesized compounds were conﬁrmed by spectral
data (IR, NMR and mass spectra). Elemental (C, H, N) anal-
ysis satisfactorily conﬁrmed elemental composition and purity
of the synthesized compounds.
4.2. Antihistaminic activity
A series of compounds containing triazolo[4,3-a]quinazolin-
5(4H)-one ring system have been evaluated for their in vivo
antihistaminic activity. Protection against histamine induced
bronchospasm on conscious guinea pigs method was adopted
to determine the antihistaminic potential of the test com-
pounds. All of them have been found to exhibit signiﬁcant
antihistaminic activity (Table 1). Percentage protection data
showed that all test compounds of the series show signiﬁcant
protection in the range of 66–69%. Structure activity relation-
ship (SAR) studies indicated that different substituents on the
C-1, exerted varied biological activity. It has been found that
the presence of methyl group showed better activity over the
unsubstituted compounds. When chain length increased from
methyl to ethyl and propyl the activity decreased. Replacement
of a proton of the methyl group by chloro showed further
decrease in activity while the order of activity was
methyl > ethyl > unsubstituted > propyl > chloromethyl.
Among the series, 4-(3-chloromethyl)-1-methyl-[1,2,4]triazol-
o[4,3-a]quinazolin-5(4H)-one (S5) was the most potent with
the percentage protection of 69.65 and it is comparable to that
of standard chlorpheniramine maleate (70.09%). As the test
compounds could not be converted to water-soluble form,
in vitro evaluation for antihistaminic activity could not be
performed.
4.3. Sedative-hypnotic activity
As sedation is one of the major side effects associated with
antihistamines, the test compounds were also evaluated for
their sedative potentials. Sedative-hypnotic activity was deter-
mined by measuring the reduction in motor activity. The re-
sults of this study (Table 1) showed that almost all the test
compounds were found to exhibit mild activity (less than
10%). Cetirizine and chlorpheniramine maleate were used as
references, chlorpheniramine showed nearly 30% of sedation
and cetirizine showed 10–13% of sedation approximately.
Compared to the reference standard chlorpheniramine maleate
(ﬁrst generation antihistamine), all the test compounds showed
lesser sedative potential; while compared to cetrizine (non-sed-
ative antihistamine) the test compounds showed equipotent
sedative activity. Hence this series can be developed as clini-
cally useful non-sedative antihistamines.
5. Conclusion
In summary, the synthesis of a new series of 1-substituted-4-(3-
chlorophenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones has
been described. These derivatives have exhibited promising
antihistaminic activity against histamine-induced broncho-
spasm on conscious guinea pigs model. Among the series
4-(3-chlorophenyl)-1-methyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (S5) was found to be the most active antihistaminic
agent, which is more potent (69.65%) than the reference stan-
dard chlorpheniramine maleate (70.09%). Interestingly the
sedative property of compound S5 was found to be negligible
(5.36%) when compared to chlorpheniramine maleate
(29.58%), therefore it could serve as a lead molecule for fur-
ther modiﬁcation to obtain a clinically useful novel class of
antihistaminic agents.
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